Sexual dysfunction comprises a group of disorders that cause a distressing reduction in the ability to respond sexually or to experience sexual pleasure. For most cases, doctors have few effective treatments to offer these patients.
S1 Biopharma is evaluating partnerships, collaborations and out-licensing deals that will enable the company to rapidly advance its sexual dysfunction franchise as well as to accelerate the path to commercialization for its drug candidates in the U.S. and internationally.
February 12 – 13, 2018
New York, New York
March 12 – 14, 2018
Amsterdam, The Netherlands
May 14-16, 2018
Ghent, Belgium